Lv4
500 积分 2023-07-10 加入
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
13天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
13天前
已完结
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations
23天前
已完结
Overview and Current Status of Peptide Receptor Radionuclide Therapy
23天前
已完结
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges
1个月前
已完结
Efficacy and Safety of 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment
1个月前
已完结
Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases
4个月前
已完结
Is Delayed Image of 18F-FDG PET/CT Necessary for Mediastinal Lymph Node Staging in Non–Small Cell Lung Cancer Patients?
5个月前
已完结
Clinical Features and Management of Congenital Fibrinogen Deficiencies
5个月前
已完结
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
7个月前
已完结
皖公网安备34019202002308
